Filed - Glenmark
Filed - Glenmark Filed - Glenmark
from glenmarkpharma.com
More from this publisher
13.04.2014
Views
Summary 31
Summary-Key target milestones by FY 2007 Research Conclude 1 more licensing deal for NCEs by End FY 2007 Aim to progress Phase II for GRC 8200 and GRC 3886; initiate Phase I trials on 3 NCE compounds (GRC 10693, 6211 and 10801) Formulations APIs Conclude 1 acquisition in Europe In-license novel products/co-marketing deals Market 18-22 ANDAs in the US market File 15-20 solid dose ANDAs and another 6 topicals; include XRs and P-IV opportunities File 12-14 DMFs Commence construction in Aurangabad, expand Ankhleshwar 32
- Page 2 and 3: Disclaimer This presentation has be
- Page 4 and 5: Background History 29-year old com
- Page 6 and 7: Strategic roadmap: Transform into a
- Page 8 and 9: Research and Development 5
- Page 10 and 11: Licensing Strategy Partner Selectio
- Page 12 and 13: NCE Pipeline Lead Target Indication
- Page 14 and 15: NCE Pipeline Lead Target Indication
- Page 16 and 17: Generic Formulations 13
- Page 18 and 19: USA - Generic Formulations Current
- Page 20 and 21: Europe - Start-up phase Strategy &
- Page 22 and 23: Latin America Going forward Exp
- Page 24 and 25: India Formulations Current Status
- Page 26 and 27: India Formulations Moving forward,
- Page 28 and 29: Active Pharmaceutical Ingredients C
- Page 30 and 31: Financials and Projections Performa
- Page 32 and 33: Financials and Projections Mileston
- Page 36: Thank you 33
Summary<br />
31
Change language